These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 8578476

  • 1. New antiplatelet agents: platelet GPIIb/IIIa antagonists.
    Coller BS, Anderson K, Weisman HF.
    Thromb Haemost; 1995 Jul; 74(1):302-8. PubMed ID: 8578476
    [Abstract] [Full Text] [Related]

  • 2. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ, Satler LF.
    J Invasive Cardiol; 1994 Jul; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [Abstract] [Full Text] [Related]

  • 3. The anti-GPIIb-IIIa agents: fundamental and clinical aspects.
    Coller BS, Anderson KM, Weisman HF.
    Haemostasis; 1996 Oct; 26 Suppl 4():285-93. PubMed ID: 8979134
    [Abstract] [Full Text] [Related]

  • 4. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
    Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF.
    J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
    [Abstract] [Full Text] [Related]

  • 5. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators.
    Mark DB, Talley JD, Topol EJ, Bowman L, Lam LC, Anderson KM, Jollis JG, Cleman MW, Lee KL, Aversano T, Untereker WJ, Davidson-Ray L, Califf RM.
    Circulation; 1996 Aug 15; 94(4):629-35. PubMed ID: 8772681
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".
    Reverter JC, Béguin S, Kessels H, Kumar R, Hemker HC, Coller BS.
    J Clin Invest; 1996 Aug 01; 98(3):863-74. PubMed ID: 8698879
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
    Turner NA, Moake JL, Kamat SG, Schafer AI, Kleiman NS, Jordan R, McIntire LV.
    Circulation; 1995 Mar 01; 91(5):1354-62. PubMed ID: 7867173
    [Abstract] [Full Text] [Related]

  • 10. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A.
    Thromb Haemost; 1998 Dec 01; 80(6):994-1001. PubMed ID: 9869173
    [Abstract] [Full Text] [Related]

  • 11. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.
    Simoons ML, de Boer MJ, van den Brand MJ, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, van der Wieken LR, de Bono D, Rutsch W, Schaible TF.
    Circulation; 1994 Feb 01; 89(2):596-603. PubMed ID: 7508826
    [Abstract] [Full Text] [Related]

  • 12. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
    EPIC Investigators.
    N Engl J Med; 1994 Apr 07; 330(14):956-61. PubMed ID: 8121459
    [Abstract] [Full Text] [Related]

  • 13. The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease.
    Lefkovits J, Topol EJ.
    Cleve Clin J Med; 1996 Apr 07; 63(3):181-9. PubMed ID: 8665658
    [Abstract] [Full Text] [Related]

  • 14. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
    Reininger AJ, Agneskirchner J, Bode PA, Spannagl M, Wurzinger LJ.
    Thromb Haemost; 2000 Feb 07; 83(2):217-23. PubMed ID: 10739376
    [Abstract] [Full Text] [Related]

  • 15. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP, Schuster P.
    Z Kardiol; 2003 Mar 07; 92(3):213-8. PubMed ID: 12658467
    [Abstract] [Full Text] [Related]

  • 16. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
    Giordano A, Musumeci G, D'Angelillo A, Rossini R, Zoccai GB, Messina S, Coscioni E, Romano S, Romano MF.
    Curr Drug Metab; 2016 Mar 07; 17(2):194-203. PubMed ID: 26652157
    [Abstract] [Full Text] [Related]

  • 17. Platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease.
    Lefkovits J, Topol EJ.
    Curr Opin Cardiol; 1995 Jul 07; 10(4):420-6. PubMed ID: 7549085
    [Abstract] [Full Text] [Related]

  • 18. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
    Ghaffari S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, Ferguson JJ, Miller DP, Califf RA, Topol EJ.
    Am J Cardiol; 1998 Jul 01; 82(1):7-12. PubMed ID: 9671000
    [Abstract] [Full Text] [Related]

  • 19. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG InvestigatorsDepartment of Cardiology, Cleveland Clinic Foundation, OH 44195, USA..
    N Engl J Med; 1997 Jun 12; 336(24):1689-96. PubMed ID: 9182212
    [Abstract] [Full Text] [Related]

  • 20. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators.
    Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M.
    Lancet; 1994 Apr 09; 343(8902):881-6. PubMed ID: 7908357
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.